Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings

Rhea-AI Summary

Reneo Pharmaceuticals will present a poster on their selective PPARδ agonist, mavodelpar, at upcoming scientific meetings. The drug shows potential as a therapeutic option for mitochondrial myopathies.

Positive

• Reneo Pharmaceuticals will present findings on mavodelpar, a selective PPARδ agonist that improves cellular bioenergetics in fibroblasts from patients with mitochondrial complex I deficiency. The drug has potential as a therapeutic option for primary mitochondrial myopathies.

Negative

• None.

IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the company will present a poster titled “Selective peroxisome proliferator-activated receptor (PPAR) delta (δ) agonist, mavodelpar, improves cellular bioenergetics in fibroblasts from patients with mitochondrial complex I deficiency” at the following upcoming scientific meetings.

PittGene Meeting
Date: Wednesday, October 25, 2023, at 2:00-2:45pm ET
Location: University Club at University of Pittsburgh, Pittsburgh, PA
Presenter: Bianca Seminotti, PhD

Translational Research in Mitochondria, Metabolism, Aging and Disease (TRiMAD) Meeting 2023
Date: Monday, November 6, 2023, at 5:30-7:00pm ET
Location: University Club at University of Pittsburgh, Pittsburgh, PA
Presenter: Bianca Seminotti, PhD

In this presentation, Reneo and collaborators will report findings which demonstrate that the bioenergetic deficiencies and mitochondrial dysfunction observed in CI-deficient patient fibroblasts can potentially be alleviated by treatment with mavodelpar, a potent and selective PPARδ agonist. Furthermore, because mavodelpar activation results in increased transcription of genes involved in mitochondrial biogenesis, fatty acid oxidation and energy production in the form of ATP, these results provide mechanistic evidence for the potential of mavodelpar as a therapeutic option in this and similar types of primary mitochondrial myopathies (PMM).

Mavodelpar is an investigational drug product candidate that is under clinical investigation, and which has not yet been approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, or any other regulatory agency.

About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Danielle Spangler 
Investor Relations 
Reneo Pharmaceuticals, Inc. 
dspangler@reneopharma.com

Matthew Purcell, Pharm.D.
Media Inquiries 
Russo Partners, LLC 
matthew.purcell@russopartnersllc.com

What is Reneo Pharmaceuticals presenting at upcoming scientific meetings?

Reneo Pharmaceuticals is presenting a poster on mavodelpar, a selective PPARδ agonist.

What are the potential benefits of mavodelpar?

Mavodelpar has shown potential in improving cellular bioenergetics in patients with mitochondrial complex I deficiency, making it a possible therapeutic option for primary mitochondrial myopathies.

Is mavodelpar approved for marketing?

No, mavodelpar is still under clinical investigation and has not yet been approved for marketing by regulatory agencies.